News Releases
Merus to Participate in Upcoming Investor Conferences
Merus Announces Pricing of Public Offering of Common Shares
Merus N.V. Announces Proposed Public Offering of Common Shares
Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies
Merus Announces Collaborations with Nationwide Medical Organizations in the Netherlands and Japan to Enhance Screening and Identification of Cancer Patients with NRG1 Fusion Tumors and to Raise Awareness of the eNRGy Clinical Trial
Merus Announces Presentation of Phase 1 Clinical Data for MCLA-158 at the American Society of Clinical Oncology (ASCO) 2021 Gastrointestinal Cancers Symposium
Merus Granted FDA Fast Track Designation of Zenocutuzumab for the Treatment of Patients with Neuregulin 1 Fusion Cancers
Merus and Sema4 Enter Into an Agreement to Support Merus’ Phase 1/2 Clinical Trial of Zenocutuzumab
Merus to Present at the Jefferies Virtual London Healthcare Conference
Merus Announces Poster Presentations on MCLA-145 at Society for Immunotherapy of Cancer
Merus Announces Financial Results for the Third Quarter and Provides Business Update
Merus and myTomorrows Announce Expansion of Collaboration for Screening and eNRGy Clinical Trial Awareness for Cancer Patients with Neuregulin 1 Fusion Tumors
Merus to Present at the 2020 Wedbush PacGrow Healthcare Conference
Merus Announces Financial Results for the Second Quarter and Provides Business Update
Merus Appoints Andrew Joe, M.D., as Chief Medical Officer
Merus announces FDA Orphan Drug Designation of Zenocutuzumab for the Treatment of Pancreatic Cancer
Merus and Caris Life Sciences Announce Collaboration to Detect NRG1 Fusions in Cancer Patients
Merus to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference
Merus Announces the Acceptance of Six Abstracts at Upcoming Medical Conferences and Provides Program Updates
Merus Announces Financial Results for the First Quarter and Provides Business Update
Merus Announces Financial Results for the Fourth Quarter and Full Year 2019 and Provides Business Update
Merus Announces Chief Executive Officer Transition
Merus Announces Financial Results for the Third Quarter 2019 and Provides Business Update
Merus Announces Pricing of Public Offering of Common Shares
Merus N.V. Announces Proposed Underwritten Public Offering of Common Shares
Merus Bispecific Antibody MCLA-128 Shows Encouraging Early Clinical Activity in Patients with Cancers Harboring NRG1 Gene Fusions
Merus Announces Presentation and Poster on MCLA-128 and MCLA-129 Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Merus Announces Financial Results for the Second Quarter 2019 and Provides Business Update
Merus to Present at the Jefferies 2019 Healthcare Conference
Merus Announces Financial Results for the First Quarter 2019 and Provides Business Update
Merus Announces 2019 Annual General Meeting of Shareholders
Merus to Present at the RBC Capital Markets 2019 Healthcare Conference
Merus Announces First Patient Treated in Phase 1 Clinical Trial of MCLA-145 for Advanced Solid Tumors
Merus Announces Financial Results for the Full Year 2018 and Provides Business Update
Merus and Incyte Present MCLA-145 Program Preclinical Data at the AACR Annual Meeting 2019
Merus to Present at the Cowen & Co. 39th Annual Health Care Conference
Merus to Participate in Guggenheim Healthcare Talks Idea Forum
Merus Announces IND Clearance for MCLA-145
Merus Announces Strategic Collaboration with Betta Pharmaceuticals to Develop and Commercialize MCLA-129 in China
Merus Announces Financial Results for the Third Quarter 2018 and Provides Business Update
Merus Announces Global Settlement and End to All Patent Litigation with Regeneron Pharmaceuticals
Merus to Present at the Jefferies 2018 London Healthcare Conference
Merus to Present at the Cantor Fitzgerald Global Healthcare Conference
Merus Strengthens Team with Key Appointments
Merus to Participate in Citi’s 13th Annual Biotech Conference
Merus Announces Formation of a Scientific Advisory Board
Merus Announces Financial Results for the Second Quarter 2018 & Mid-year Operating Results
Merus Announces Recent Corporate Developments and Financial Results for the First Quarter 2018
Merus Announces Recent Corporate Developments and Financial Results for the First Quarter 2018
Merus Announces Annual Meeting of Shareholders
Merus to Present at the Jefferies 2018 Healthcare Conference
UTRECHT, The Netherlands , May 31, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics ® ), today announced that Hui Liu , Ph.D., Executive Vice President and Chief Business Officer, will
Merus Announces First Patient Dosed in Phase 1 Clinical Trial of MCLA-158 in Patients with Solid Tumors
- IND Accepted in April by the U.S. FDA for MCLA-158 - UTRECHT, The Netherlands , May 24, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the first patient has been
Merus Announces Unique Mechanism of Action of MCLA-128 That Potently Blocks HER3 Signaling Published in Cancer Cell
UTRECHT, The Netherlands , May 15, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced the unique mechanism of action (MOA) of MCLA-128, the Company’s most-advanced
Merus Announces Recent Corporate Developments and Financial Results for the Fourth Quarter and Full Year 2017
- Phase 2 combination trial in two metastatic breast cancer (MBC) populations initiated for Merus’ most advanced bispecific antibody candidate, MCLA-128 - - Strategic collaboration announced with Simcere Pharmaceutical Group for multiple bispecific antibodies; expanded collaboration with Ono
Merus to Report Full Year 2017 Financial Results and Corporate Developments on April 26, 2018
Conference call scheduled for Thursday, April 26, 2018, at 8:30 a.m. ET UTRECHT, The Netherlands , April 19, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the